The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.
 
Mostafa Eyada
No Relationships to Disclose
 
Bryan M. Fellman
No Relationships to Disclose
 
Shrina Patel
No Relationships to Disclose
 
Victoria Michael
No Relationships to Disclose
 
Pamela T. Soliman
Consulting or Advisory Role - AADi; Amgen; Clovis Oncology; Eisai; GlaxoSmithKline; WebMD
Research Funding - Incyte (Inst); Leap Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Travis T. Sims
Research Funding - Bristol Myers Squibb Foundation; Gilead Sciences
 
Jeffrey Andrew How
Research Funding - MacroGenics; Merck
 
Amir A. Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Gerson Lehrman Group; Guidepoint Global
Consulting or Advisory Role - Adicet Bio; Iovance Biotherapeutics; Macrogenics; Theolytics
Research Funding - Aravive (Inst); AstraZeneca (Inst); Avenge Bio (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); immatics (Inst); Imunon (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Stryker
 
Nicole D. Fleming
Consulting or Advisory Role - GlaxoSmithKline; Immunogen; Pfizer; Tesaro
 
Lois M. Ramondetta
No Relationships to Disclose
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; Nuvectis Pharma; OncLive; pharma&; Roche; Seagen; Targeted Oncology; Vaniam Group; Verastem; Vincerx Pharma; Zentalis; ZielBio
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Jazz Pharmaceuticals (Inst); Mereo BioPharma (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Roche/Genentech (Inst); Zentalis (Inst)